Latest Headlines
CATEGORY
-
2023-03-29PM Lee receives a first-hand update by Biosyngen on its progress in cell therapyThe city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-long visit to China. Accompanying PM Lee in this trip are Foreign Minister Vivian Balakrishnan, Trade and Industry Minister Gan Kim Yong, Health Minister Ong Ye Kung, Senior Minister of State for ForeREAD MORE -
2023-02-17Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal CancerFebruary 16th, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") was granted approval by US FDA for the company's IND application for BRG01 cell therapy, path the way for Phase I/II clinical trial. BRG01 is an autologous T cell therapy for relapsed/metastatic nasopharyngeal cancer (NPC) treatmentREAD MORE -
2022-12-14IND Application of Biosyngen’s Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPAOn Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as “Biosyngen”) made an announcement on the approval granted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the company’s IND application for BRG01 Therapy. BRG01 Therapy is an autoREAD MORE -
2022-11-16Biosyngen featured in the “Top 50 Most Innovative Companies of Chinese Biomedicine in 2022”, Pharma BigstarOn November 10th to 11th, 2022, the Shanghai (Minhang) Biopharmaceutical Industry Innovation Summit and the Universal Cell Therapy Development Forum 2022 were successfully held in Shanghai. The "Top 50 Most Innovative Biopharmaceutical Companies in China 2022" was unveiled during the forum.READ MORE -
2022-10-20Prof. Jean Paul Thiery, Biosyngen’s Chief Scientist, is ranked among the World’s Top 2% Clinical Scientists 2022Professor Jean Paul Thiery, Biosyngen’s Chief Scientist and Chairman of Scientific Advisory Board, is featured in the World’s Top 2% Clinical Scientists 2022. Published by John P.A.Joannidis’ of Stanford University, this ranking recognizes impactful and influential clinical researchers around the wREAD MORE -
2022-09-28The IND application of Biosyngen BRG01 Therapy was accepted by CDEGUANGZHOU, China, Sept. 28, 2022 /PRNewswire/ -- The IND application of Biosyngen BRG01 Therapy has been accepted for review by the Center for Drug Evaluation, China (CXSL2200487)（https://www.cde.org.cn/main/xxgk/listpageREAD MORE -
2022-09-28Biosyngen Gives Cell Therapy GMP Capabilities in Singapore A BoostSINGAPORE, Sept. 28, 2022 /PRNewswire/ -- On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a base to develop the company's immunotherapy assets to address unmet needs in cancer treatment.READ MORE -
2022-05-28Embracing Win-win Cooperation - ASEAN Consul Generals, officials and representatives of chambers of commerce in Guangzhou visited BiosyngenGUANGZHOU, China, May 28, 2022 /PRNewswire/ -- On the morning of May 27, 2022, Mr. Loh Tuck Keat, Consul General of Singapore in Guangzhou, and representatives of Consulates General and Chambers of Commerce of eight countries, namely Malaysia, Philippines, Laos, Vietnam, Indonesia, Thailand and CambREAD MORE -
2022-01-15French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge CityGUANGZHOU, ChinaJan. 15, 2022 /PRNewswire/ -- On the afternoon of January 14th, Mr. Sylvain FOURRIERE, Consul General of France in Guangzhou, and officers from consulates general of 9 countries including Britain, Canada and Switzerland visited China-Singapore Guangzhou Knowledge City and Singapore-bREAD MORE -
2021-12-29Biosyngen Pte Ltd launched biological production base for commercialization of immune cell therapeutics in ChinaGUANGZHOU, China, Dec. 29, 2021 /PRNewswire/ -- The inauguration ceremony of Biosyngen Pte. Ltd., ("Biosyngen") joint projects and Biosyngen biological production base was held in China-Singapore Guangzhou Knowledge City (CSGKC), on December 28th , 2021.READ MORE
